Soluble suppression of tumorigenicity-2 changes during cardiotoxic cancer treatment: a systematic review and meta-analysis
Luca Fazzini(Mayo Clinic), Christian Cadeddu Dessalvi(University of Cagliari), Nicola Campana(University of Cagliari), Carlo G. Tocchetti(Federico II University Hospital), Vincenzo Quagliariello(Cancer Institute (WIA)), Nicola Maurea(Cancer Institute (WIA)), Martino Deidda(University of Cagliari), Simone Angius(University of Cagliari), Giordano Maria Pugliesi(Mayo Clinic in Arizona), Pietro Ameri(Ospedale Policlinico San Martino)
Cited by 1
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
|European Heart Journal|2024|2.4k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767